ClinicalTrials.gg
RecruitingNCT07574645SPIDERUpdated May 8, 2026

Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry

An observational study in Spinal Dural Arteriovenous Fistula, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Thomas Jefferson University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Arteriovenous Fistula with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Arteriovenous Fistula · United States.

Planned enrollment
2nd of 15
1,000 · median 60
Started
2026
the only one that year
Observational
15 of 60
2 open now
Primary completion
2026-05
later than 2 of 10 live
Registered
60th of 60
by date

Among the 60 studies in Arteriovenous Fistula with a site in United States, this one is the 2nd largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2026, is one of 15 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 60th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 60 studies in Arteriovenous Fistula with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Arteriovenous Fistula with a site in United States, or all of them as a file.
02

Study summary

Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.

Read the detailed description

Type 1 or dural spinal arteriovenous fistulas (SDAVFs) are the most common spinal vascular malformation but remain frequently underdiagnosed due to their insidious onset and nonspecific clinical presentation. Delayed diagnosis is common and often results in progressive, and sometimes irreversible, myelopathy. Despite advances in imaging and treatment, there remains significant variability in diagnostic timelines, treatment strategies (endovascular, surgical, or combined), and reported outcomes across institutions.

Existing literature is largely limited to single-center retrospective series or small cohorts, often underpowered to evaluate predictors of outcome, recurrence, and the impact of diagnostic delay. Furthermore, direct comparisons between treatment modalities and long-term functional outcomes using standardized clinical scales are limited.

The SPIDER registry is designed to address these gaps by creating the largest international, multicenter dataset of patients with spinal dural AVFs. By pooling de-identified data from high-volume centers worldwide, this study aims to provide robust, generalizable evidence to inform clinical decision-making and optimize patient outcomes.

03

Conditions studied

  • Spinal Dural Arteriovenous Fistula

Browse trials for

Keywords

  • spinal dural arteriovenous fistula
  • spinal arteriovenous malformation
  • spinal AVF
  • sdAVF
  • international
  • multicenter
  • registry
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry will include patients from 40 different hospitals in 20 different countries.

Eligibility criteria

Inclusion Criteria:

  • Type 1 spinal dural arteriovenous fistula, confirmed on imaging
  • Surgically or endovascularly treated
  • At least 1 available primary outcome
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Treatment success

    Complete surgical/endovascular obliteration of the fistula

    Time frame: Recorded at the end of the embolization or surgery.

  2. Recurrence

    Fistula recurrence

    Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

  3. Status of symptoms at last clinical follow-up

    Improved, unchanged, or worsened pain, sensory, and motor symptoms

    Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

  4. Modified Aminoff-Logue Scale

    Gait and bowel/bladder score

    Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

  5. Modified Rankin Scale

    Measure of functional independence

    Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

  6. Mortality

    Time frame: Time-to-event Outcome Measures. Estimated period of time over which the event is assessed: on average 1.5 years after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data cannot be shared due to its multicenter nature.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 8, 2026
StartActual
Jan 5, 2026
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07574645
Responsible party
Pascal Jabboour (The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery and Radiology; Division Chief of Neurovascular Surgery & Endovascular Neurosurgery, Thomas Jefferson University) — Principal investigator
First posted
May 8, 2026
Start date
Jan 5, 2026
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
May 8, 2026

Study contacts

Pascal Jabbour, MD
Contact
pascal.jabbour@jefferson.edu
215-955-7000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion